Activated protein C retards recovery from coagulopathy in severe acute pancreatitis

Scandinavian Journal of Clinical and Laboratory Investigation

Volumn 76, Issue 1, 2016, Pages 10-16

  Kyhälä, Lea ^a   Lindström, Outi ^a   Kylänpää, Leena ^a   Mustonen, Harri ^a   Puolakkainen, Pauli ^a   Kemppainen, Esko ^a   Tallgren, Minna ^a   Pettilä, Ville ^a   Repo, Heikki ^b   Petäjä, Jari ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

antithrombins; coagulation factors; fibrinogen; pancreatitis; Protein C system

Indexed keywords

ACTIVATED PROTEIN C; ANTICOAGULANT AGENT; ANTITHROMBIN; C REACTIVE PROTEIN; D DIMER; DROTRECOGIN; FIBRINOGEN; INTERLEUKIN 6; PLACEBO; IL6 PROTEIN, HUMAN; PROTEIN C;

ACUTE PANCREATITIS; ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING DISORDER; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL PROTOCOL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; MALE; OUTCOME ASSESSMENT; PHYSIOLOGICAL PROCESS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SEVERE ACUTE PANCREATITIS; THROMBOPLASTIN TIME; ACUTE DISEASE; BLOOD; BLOOD COAGULATION DISORDERS; COMPLICATION; CONTROLLED CLINICAL TRIAL; MIDDLE AGED; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME;

ACUTE DISEASE; ADULT; ANTICOAGULANTS; ANTITHROMBIN PROTEINS; BLOOD COAGULATION DISORDERS; FEMALE; HUMANS; INTERLEUKIN-6; MALE; MIDDLE AGED; PANCREATITIS; PARTIAL THROMBOPLASTIN TIME; PROTEIN C; PROTHROMBIN TIME;

EID: 84947865182     PISSN: 00365513     EISSN: 15027686     Source Type: Journal    
DOI: 10.3109/00365513.2015.1084041     Document Type: Article

References (32)

1. Esmon CT. Inflammation and the activated protein C anticoagulant pathway. Semin Thromb Hemost 2006;32:49-60.
2. Deitch EA. Multiple organ failure. Pathophysiology and potential future therapy. Ann Surg 1992;216:117-34.
3. Wilson PG, Manji M, Neoptolemos JP. Acute pancreatitis as a model of sepsis. J Antimicrob Chemother 1998;41: 51-63.
4. Agarwal MB, Kamdar MS, Bapat RD, Mehta BC, Rao S, Rao PN. Consumptive coagulopathy and fibrinolysis in experimental acute pancreatitis. J Postgrad Med 1982;28:214-17.
5. Esmon CT. Protein C anticoagulant pathway and its role in controlling microvascular thrombosis and inflammation. Crit Care Med 2001;29:48-51; discussion 51-2.
6. Esmon CT. The anticoagulant and anti-inflammatory roles of the protein C anticoagulant pathway. J Autoimmun 2000;15:113-16.
7. Joyce DE, Gelbert L, Ciaccia A, DeHoff B, Grinnell BW. Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis. J Biol Chem 2001;276:11199-203.
8. Sarangi PP, Lee HW, Kim M. Activated protein C action in inflammation. Br J Haematol 2010;148:817-33.
9. Esmon CT. The protein C anticoagulant pathway. Arterioscler Thromb 1992;12:135-45.
10. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-Rodriquez A, Steingrup JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ Jr. Efficacy and safety of recombinant human activated protein C for severe sepsis N Engl J Med 2001;344:699-709.
11. Ranieri VM, Thompson BT, Barie PS, Dhainaut JF, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khalidi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD, PROWESS-SHOCK Study Group. Drotrecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64.
12. PettiläV, KyhäläL, KylänpääML, Leppäniemi A, Tallgren M, Markkola A, Puolakkainen P, Repo H, Kemppainen E. APCAP-activated protein C in acute pancreatitis: A double-blind randomized human pilot trial. Crit Care 2010;14:R139.
13. KyhäläL, Mentula P, KylänpääL, Moilanen E, Puolakkainen P, PettiläV, Repo H. Activated protein C does not alleviate the course of systemic inflammation in the APCAP trial. Int J Inflam 2012;712739.
14. Taylor FB Jr, Toh CH, Hoots WK, Wada H, Levi M. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost 2001;86:1327-30.
15. Horsti J. The Quick and Owren prothrombin time methods for oral anticoagulant therapy do not agree well using the International Normalized Ratio (INR) units. Scand J Clin Lab Invest. 2003;63:455-6.
16. Robert A, Chazouillères O. Prothrombin time in liver failure: Time, ratio, activity percentage, or international normalized ratio?. Hepatology 1996;24:1392-4.
17. Wei Y, Zheng D, Xiao L, Shi B. Comparison of modes of prothrombin time reporting in patients with advanced liver disease associated with viral hepatitis. J Thromb Thrombolysis 2010;29:81-6.
18. Hemker HC, Giesen P, AlDieri R, Reqnault V, deSmed E, Wagenwoord R, Lecompte T, Bequin S. The calibrated automated thrombogram (CAT): A universal routine test for hyper-and hypocoagulability. Pathophysiol Haemost Thromb 2002;32:249-53.
19. Lasson A, Ohlsson K. Consumptive coagulopathy, fibrinolysis and protease-antiprotease interactions during acute human pancreatitis. Thromb Res 1986;41:167-83.
20. Okajima K. Regulation of inflammatory responses by natural anticoagulants. Immunol Rev 2001;184:258-74.
21. Yuda H, Adachi Y, Taguchi O, Gabazza EC, Hataji O, Tamaki S, Nishikubo K, Fukudome K, D'Alessandro-Gabazza CN, Maruyama J, Izumizaki M, Iwase M, Homma I, Inoue R, Kamada H, Hayashi T, Kasper M, Lambrecht BN, Barnes PJ, Suzuki K. Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood 2004;103:2196-204.
22. Feistritzer C, Schuepbach RA, Mosnier LO, Bush LA, Di Cera E, Griffin JH, Riewald M. Protective signaling by activated protein C is mechanistically linked to protein C activation on endothelial cells. J Biol Chem 2006;281:20077-84.
23. Finigan JH, Dudek SM, Singleton PA, Chiang ET, Jacobson JR, Camp SM, Ye SQ, Garcia JG. Activated protein C mediates novel lung endothelial barrier enhancement: role of sphingosine 1-phosphate receptor transactivation. J Biol Chem 2005;280:17286-93.
24. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol 2005;131:417-30.
25. Carey MJ, Rodgers GM. Disseminated intravascular coagulation: clinical and laboratory aspects. Am J Hematol 1998;59:65-73.
26. Esmon CT. Thrombomodulin as a model of molecular mechanisms that modulate protease specificity and function at the vessel surface. FASEB J 1995;9:946-55.
27. Maeda K, Hirota M, Ichihara A, Ohmuraya M, Hashimoto D, Sugita H, Takamori H, Kanemitsu K, Baba H. Applicability of disseminated intravascular coagulation parameters in the assessment of the severity of acute pancreatitis. Pancreas 2006;32:87-92.
28. Sawa H, Ueda T, Takeyama Y, Yasuda T, Matsumura N, Nakajima T, Ajiki T, Fujino Y, Suzuki Y, Kuroda Y. Elevation of plasma tissue factor levels in patients with severe acute pancreatitis. J Gastroenterol 2006;41:575-81.
29. Lindström OK, Tukiainen EM, KylänpääML, Mentula PJ, Puolakkainen PA, Wartivaara-Kautto UM, Repo H, PetäjäJM. Thrombin generation in vitro and in vivo, and disturbed tissue factor regulation in patients with acute pancreatitis. Pancreatology 2011;11:557-66.
30. Alsfasser G, Warshaw AL, Thayer SP, Antoniu B, Laposata M, Lewandrowski KB, Fernandez-del Castillo C. Decreased inflammation and improved survival with recombinant human activated protein C treatment in experimental acute pancreatitis. Arch Surg 2006;141:670-6; discussion 676-7.
31. Dhainaut JF, Yan SB, Margolis BD, Lorente JA, Russell JA, Freebairn RC, Spapen HD, Riess H, Basson B, Johnson G III, Kinasewitz GT, PROWESS Sepsis Study Group. Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis. Thromb Haemost 2003;90:642-53.
32. Griffin JH, Zlokovic BV, Mosnier LO. Activated protein C: biased for translation. Blood 2015;125:2898-907.